Calcium channel blockers: monotherapy and dual therapy considerations in the treatment of hypertension.
The papers in this supplement speak to several of the issues pertinent to contemporary therapy with CCBs. The article by Dr Weir thoughtfully describes important pharmacokinetic and pharmacodynamic features of CCBs. In so doing he establishes the basis for combination CCB and ACE inhibitor therapy. Dr Frishman provides a scholarly description of the cardiovascular effects of CCBs and further elaborates on the distinctiveness of the various CCB subclasses. Finally, Dr Bakris et al. provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy
Sica
Domenic A
DA
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298-0160, USA. DSICA@HSC.VCU.EDU
D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers